Database→Larazotide

Tier 2-3Gut HealthAutoimmuneAnti-inflammatoryPREMIUM

Larazotide

Larazotide Acetate (AT-1001 / INN-202) — Synthetic Octapeptide Tight Junction Regulator

Not FDA-approved. Phase 3 (CedLara) discontinued June 2022 by 9 Meters Biopharma following interim analysis showing insufficient effect size. FDA Fast Track designation previously granted. No NDA filed. Research compound only.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

Larazotide acetate (AT-1001) is a synthetic 8-amino acid peptide derived from Vibrio cholerae zonula occludens toxin, engineered as a competitive zonulin receptor antagonist to prevent tight junction opening in the intestinal epithelium. It is the most clinically developed tight junction regulator ever studied in humans: a 342-patient Phase 2b RCT met its primary endpoint (26% reduction in celiac disease symptomatic days at 0.5 mg TID, p=0.022), but Phase 3 was discontinued in June 2022 at interim analysis due to insufficient effect size. Zero systemic absorption was detected across 828+ subjects. Not FDA-approved for any indication.

🔒

Full Profile: Premium Members Only

The complete Larazotide profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use